Bristol-Myers Squibb Company – Product Pipeline Review – 2012 - Global Market Direct's pharmaceuticals report, "Bristol-Myers Squibb Company - Product Pipeline Review - 2012" provides data on the Bristol-Myers Squibb Company's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from our proprietary databases, Bristol-Myers Squibb Company's corporate website, SEC filings, investor presentations and featured press releases, both from Bristol-Myers Squibb Company and industry-specific third party sources, put together by our team.
Scope
- Bristol-Myers Squibb Company - Brief Bristol-Myers Squibb Company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Bristol-Myers Squibb Company human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Bristol-Myers Squibb Company with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Bristol-Myers Squibb Company's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Bristol-Myers Squibb Company's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Bristol-Myers Squibb Company in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Bristol-Myers Squibb Company's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Bristol-Myers Squibb Company.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Bristol-Myers Squibb Company and identify potential opportunities in those areas.
Table of Contents
Table of Contents
List of Tables
List of Figures
Bristol-Myers Squibb Company Snapshot
Bristol-Myers Squibb Company Overview
Key Information
Key Facts
Bristol-Myers Squibb Company – Research and Development Overview
Key Therapeutic Areas
Bristol-Myers Squibb Company – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Bristol-Myers Squibb Company – Pipeline Products Glance
Bristol-Myers Squibb Company – Late Stage Pipeline
Bristol-Myers Squibb Company Clinical Stage Pipeline Products
Bristol-Myers Squibb Company – Early Stage Pipeline Products
Bristol-Myers Squibb Company – Drug Profiles
abatacept
AM-095
Angiocept + FOLFIRI
AP-2966
apixaban
Aromasina + Dasatinib
asunaprevir
Atazanavir + Lamivudine + Ritonavir
avagacestat
BMS-241027
BMS-477118 + BMS-512148 + Metformin
BMS-540215 + Erbitux + Irinotecan
BMS-582664 + FOLFIRI
BMS-650032 + Pegasys + Copegus
BMS-663068
BMS-663068 + Raltegravir + Tenofovir
BMS-690514
BMS-690514 + Letrozole
BMS-690514 + Paclitaxel + Carboplatin
BMS-734016 + RG7204
BMS-754807
BMS-754807 + Erbitux
BMS-754807 + Femara
BMS-754807 + Herceptin
BMS-754807 + Paclitaxel + Carboplatin
BMS-770767
BMS-770767 + Metformin
BMS-777607
BMS-790052 + BMS-650032
BMS-790052 + BMS-650032 + Pegylated-Interferon Alpha + Ribavirin
BMS-790052 + Pegylated Interferon Alfa 2a + Ribavirin
BMS-790052 + PSI-7977
BMS-790052 + TMC435
BMS-790052 + TMC435 + Ribavirin
BMS-791325
BMS-791325 + Pegasys + Copegus
BMS-795311
BMS-817378
BMS-817399
BMS-820132
BMS-823778
BMS-824393
BMS-830216
BMS-833923
BMS-833923 + Carboplatin + Etoposide
BMS-833923 + Cisplatin + Capecitabine
BMS-833923 + Sprycel
BMS-844203 + Paclitaxel + Carboplatin
BMS-852927
BMS-866949
BMS-903452
BMS-906024
BMS-906024 + 5-Fluorouracil + Leucovorin + Irinotecan
BMS-906024 + Carboplatin + Paclitaxel
BMS-911543
BMS-914143 + BMS-650032 + Ribavirin
BMS-914143 + BMS-790052 + BMS-650032
BMS-914143 + BMS-790052 + BMS-650032 + Ribavirin
BMS-914143 + BMS-790052 + Ribavirin
BMS-914392
BMS-927711
BMS-929075
BMS-936557
BMS-936558 + Gemcitabine + Cisplatin
BMS-936558 + Ipilimumab
BMS-936558 + Paclitaxel + Carboplatin
BMS-936558 + Pemetrexed + Cisplatin
BMS-936558 + Sunitinib
BMS-936559
BMS-936564
BMS-936564 + Revlimid + Dexamethasone
BMS-936564 + Velcade + Dexamethasone
BMS-945429 + Methotrexate
BMS-954561
BMS-962476
BMS-981164
BMS-982470
BMS-982470 + BMS-936558
BMS-982470 + Yervoy
BMS-986001
BMS-986001 + Sustiva + Lamivudine
BMS-986202
brivanib alaninate
Brivanib Alaninate + 5-Fluorouracil + Leucovorin
Brivanib Alaninate + Capecitabine
Brivanib Alaninate + Docetaxel
Brivanib Alaninate + Doxorubicin
Brivanib Alaninate + Ixabepilone
Brivanib Alaninate + Paclitaxel
Cetuximab + Cisplatin + Vinorelbine
daclatasvir
dapagliflozin
Dasatinib + Capecitabine
Dasatinib + Docetaxel
Dastinib + Docetaxel + Prednisone
Eefavirenz + Didanosine + Emtricitabine
EHT/AGN-0001
EHT/AGN-0002
Elotuzumab +Thalidomide + Dexamethasone + Cyclophosphamide
GPR119 Agonist
GR Agonist
HCV Nucleotides Program
IKur Antagonists
IL-23 Adnectin
INX-189 + Pegasys + Copegus
IPH-2102
ipilimumab
Ipilimumab + Dacarbazine
Ipilimumab + Paclitaxel + Carboplatin
Ixabepilone + Carboplatin
Ixabepilone + Cetuximab
Ixabepilone + Trastuzumab
Ixempra
Ixempra + Cisplatin
Letrozole + Dasatinib
LPA Targets
LXR Modulators
MDX-1110
MDX-1203
MDX-1204
MDX-1411
MDX-1414
noscapine
NTC-801
ONO-4538
PEG-FGF-21
PEG-Interferon Lambda + Ribavirin
peginterferon lambda-1a
PSI-7977 + BMS-790052 + Ribavirin
Reyataz + Cobicistat
saxagliptin hydrochloride
Sprycel + Faslodex
Sprycel + Revlimid + Dexamethasone
succinylcholine chloride
Thymoglobulin + Belatacept + Mycophenolate Mofetil
Thymoglobulin + Belatacept + Sirolimus
Triple Reuptake Inhibitors
urelumab
XL-475
Yervoy + Etoposide + Cisplatin + Carboplatin
Bristol-Myers Squibb Company – Pipeline Analysis
Bristol-Myers Squibb Company – Pipeline Products by Therapeutic Class
Bristol-Myers Squibb Company – Pipeline Products By Target
Bristol-Myers Squibb Company – Pipeline Products by Route of Administration
Bristol-Myers Squibb Company – Pipeline Products By Mechanism of Action
Bristol-Myers Squibb Company – Recent Pipeline Updates
Bristol-Myers Squibb Company - Dormant Projects
Bristol-Myers Squibb Company - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Bristol-Myers Squibb Company – Company Statement
Bristol-Myers Squibb Company – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Bristol-Myers Squibb Company - Key Manufacturing Facilities
Bristol-Myers Squibb Company, Recent Developments
Bristol-Myers Squibb Company- Press Release
Financial Deals Landscape
Bristol-Myers Squibb Company, Deals Summary
Bristol-Myers Squibb Company, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Private Equity
Partnerships
Licensing Agreements
Equity Offering
Debt Offering
Asset Transactions
Acquisition
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Bristol-Myers Squibb Company, Key Information
Bristol-Myers Squibb Company, Key Facts
Bristol-Myers Squibb Company – Pipeline by Indication, 2012
Bristol-Myers Squibb Company – Pipeline by Stage of Development, 2012
Bristol-Myers Squibb Company – Monotherapy Products in Pipeline, 2012
Bristol-Myers Squibb Company – Combination Treatment Modalities in Pipeline, 2012
Bristol-Myers Squibb Company – Filed, 2012
Bristol-Myers Squibb Company – Phase III, 2012
Bristol-Myers Squibb Company – Phase II, 2012
Bristol-Myers Squibb Company – Phase I, 2012
Bristol-Myers Squibb Company – Pre-Clinical, 2012
Bristol-Myers Squibb Company – Pipeline By Therapeutic Class, 2012
Bristol-Myers Squibb Company - Pipeline By Target, 2012
Bristol-Myers Squibb Company – Pipeline By Route of Administration, 2012
Bristol-Myers Squibb Company – Pipeline Products By Mechanism of Action, 2012
Bristol-Myers Squibb Company – Recent Pipeline Updates, 2012
Bristol-Myers Squibb Company - Dormant Developmental Projects,2012
Bristol-Myers Squibb Company - Discontinued Pipeline Products, 2012
Bristol-Myers Squibb Company, Other Locations
Bristol-Myers Squibb Company, Subsidiaries
Bristol-Myers Squibb Company, Key Manufacturing Facilities
Bristol-Myers Squibb Company, Deals Summary
Xdx Secures $14.4 Million In Series G Financing Round
Adnexus Therapeutics Secures $15.5 Million In Series C Financing
Amira Pharma Secures $25 Million In Series B Financing
Adnexus Therapeutics Secures $27 Million In Series B Financing
Nordic Capital Fund And Avista Capital Partners Acquire ConvaTec From Bristol-Myers Squibb
Avista Capital Partners Acquires Bristol-Myers Squibb Medical Imaging From Bristol-Myers Squibb
Dainippon Enters Into Licensing Agreement With Bristol-Myers
Vanderbilt University Enters Into Agreement With Bristol-Myers Squibb To Develop Drugs For Parkinson's Disease
Life Technologies Enters Into Agreement With Bristol-Myers Squibb For Companion Diagnostics Development
Saladax Biomedical Expands Co-Development Agreement With Bristol-Myers Squibb
Prosetta Enters Into Co-Development Agreement With Bristol-Myers Squibb For Antiviral Drugs
Bristol-Myers Squibb Enters Into Co-Development Agreement With Emory University
Scripps Research Institute Enters Into Research Agreement With Bristol-Myers Squibb
Bristol-Myers Squibb Enters Into Co-Development Agreement With Tsinghua University
Bristol-Myers Squibb Enters Into Co-Development Agreement With Meso Scale
Bristol-Myers Squibb Enters Into Co-Development Agreement With Duke Translational Medicine Institute
Ensemble Therapeutics Extends Co-Development Agreement With Bristol-Myers Squibb
Bristol-Myers Squibb Enters Into Research Agreement With Gladstone Institutes
NeurOp Extends Drug Discovery Agreement With Bristol-Myers Squibb
Bristol-Myers Squibb Expands Co-Development Agreement With Simcere Pharma For BMS-795311
Dako Enters Into Co-Development Agreement With Bristol-Myers
Tranzyme Pharma Extends Co-Development Agreement With Bristol-Myers Squibb
Bristol-Myers Squibb Enters Into Co-Development Agreement With Ambrx
Bristol-Myers Squibb Expands Co-Development Agreement With Ono Pharma
Bristol-Myers Squibb, Saladax Biomedical And Ortho-Clinical Diagnostics Expand Co-Development Agreement
Bristol-Myers Squibb Enters Into Co-Development Agreement With Ono Pharma For ORENCIA
BAC Enters Into Co-Development Agreement With Bristol-Myers Squibb
GNS Healthcare Enters Into Co-Development Agreement With Bristol-Myers Squibb
Bristol-Myers Squibb Enters Into Co-Marketing Agreement With Matrix Labs
Hoffmann-La Roche Enters Into Co-Development Agreement With Bristol-Myers Squibb
Opko Health Enters Into An Agreement With Bristol-Myers Squibb
Bristol-Myers Squibb Enters Into Co-Development Agreement With Simcere Pharma For BMS-817378
Exelixis Enters Into Collaboration With Bristol-Myers Squibb
Saladax Biomedical Enters Into Co-Development Agreement With Bristol-Myers Squibb
Bristol-Myers Squibb Enters Into An Agreement With ICON And PAREXEL
AstraZeneca Pharma Enters Into Co-Development Agreement With Bristol-Myers
Bristol-Myers Squibb Enters Into Drug Discovery Collaboration With NeurOp
KineMed Broadens Co-Development Agreement With Bristol-Myers Squibb
Tranzyme Pharma Enters Into Research Agreement With Bristol-Myers Squibb
Asterand Expands Collaboration With Bristol-Myers Squibb
DxS Enters Into Co-Development Agreement With Bristol-Myers Squibb And ImClone Systems
KineMed Enters Into Co-Development Agreement With Bristol-Myers Squibb
Ensemble Discovery Enters Into Co-Development Agreement With Bristol-Myers Squibb
Bristol-Myers Squibb Extends Co-Development Agreement With Otsuka
Bristol Enters Into Co-Marketing Agreement With Otsuka
Otsuka Pharma Enters Into Agreement With Bristol-Myers
Bristol-Myers Squibb Extends Research Agreement With Tekmira Pharma
DxS Enters Into Co-Development Agreement With Bristol-Myers And ImClone Systems
XDx Enters Into Co-Development Agreement With Bristol-Myers Squibb
Bristol-Myers Squibb Enters Into Collaboration Agreement With Exelixis
Exelixis Enters Into Collaboration Agreement With Bristol-Myers Squibb
Bristol-Myers Squibb Expands Co-Development Agreement With AstraZeneca
Exelixis Enters Into Agreement With Bristol-Myers Squibb For XL413
Exelixis Extends Research Collaboration Agreement With Bristol-Myers Squibb
Bristol-Myers Squibb Enters Into An Agreement With PDL BioPharma
Bristol-Myers Squibb Enters Into Co-Development Agreement With Tekmira Pharma
Dako Enters Into Co-Development Agreement With Bristol-Myers
Merck Serono Enters Into Distribution Agreement With Bristol-Myers
Cell Signaling Technology Extends Research Agreement With Bristol-Myers Squibb
GlaxoSmithKline Enters Into An Agreement With Amira Pharma
Exelixis Enters Into Co-Development Agreement With Bristol-Myers Squibb For XL139
Gilead Sciences Enters Into An Agreement With Bristol-Myers Squibb
Ambit Extends Agreement With Bristol-Myers
Merck Serono Signs An Agreement With ImClone And Bristol-Myers Squibb
Exelixis Extends Research Collaboration With Bristol-Myers Squibb
Bristol-Myers Squibb Enters Into An Agreement With Pfizer
Bristol-Myers Ammends Co-Development Agreement With ImClone Systems
Immunicon Corporation Enters Into Research Agreement With Bristol-Myers Squibb
Bristol-Myers Enters Into Co-Development Agreement With Pfizer
Syngene International Enters Into Research Partnership With Bristol-Myers Squibb
AstraZeneca Enters Into An Agreement With Bristol-Myers Squibb
Albany Molecular Research Enters Into A Co-Development Agreement With Bristol-Myers Squibb
Exelixis Enters Into Collaboration Agreement With Bristol-Myers Squibb
Bristol-Myers Squibb And Gilead Sciences Enters Into An Agreement For ATRIPLA
Lexicon Extends Collaboration With Bristol-Myers
Nerviano Medical Enters Into Co-Development Agreement With Bristol-Myers
Roche Signs An Agreement With Amira Pharma
Epitome Biosystems Enters Into Co-Development Agreement With Bristol-Myers Squibb
Bristol-Myers Squibb Expands Licensing Agreement With Aureus Pharma
Dyax Enters Into Licensing Agreement With ZymoGenetics
Emcure Pharma Enters Into Licensing Agreement With Bristol-Myers Squibb
Summit Enters Into Licensing Agreement With Bristol-Myers Squibb For Seglin Technology
ASLAN Pharma Enters Into Licensing Agreement With Bristol-Myers Squibb For BMS-777607
Bristol-Myers Squibb Enters Into Licensing Agreement With Gilead Sciences
Bristol-Myers Squibb Enters Into Licensing Agreement With Innate Pharma For IPH2102
KineMed Extends Licensing Agreement With Bristol-Myers Squibb
Bristol-Myers Squibb Enters Into Licensing Agreement With Oncolys BioPharma
Exelixis Enters Into Licensing Agreement With Bristol-Myers Squibb For XL475
Vanda Pharma Amends Licensing Agreement With Bristol-Myers Squibb
Allergan Enters Into Licensing Agreement With Bristol-Myers Squibb
ZymoGenetics Enters Into Licensing Agreement With Novo Nordisk
Alder BioPharma Enters Into Licensing Agreement With Bristol-Myers Squibb
Bristol-Myers Enters Into A Licensing Agreement With Nissan Chemical And Teijin Pharma
Bristol-Myers Squibb Enters Into A Collaboration With ZymoGenetics
Novo Nordisk Enters Into Licensing Agreement With ZymoGenetics For IL-21
Bristol-Myers Squibb Enters Into Licensing Agreement With Exelixis
ZymoGenetics Enters Into A Licensing Agreement With Merck Serono
Ingenuity Systems Expands Licensing Agreement With Bristol-Myers Squibb
Daiichi Sankyo Enters Into Licensing Agreement With Bristol-Myers Squibb For Mevalotin
KAI Pharma Enters Into Licensing Agreement With Bristol-Myers Squibb
Repligen Enters Into Licensing Agreement With Bristol-Myers Squibb
Inhibitex Enters Into Licensing Agreement With Cardiff University And Katholieke Universiteit
Pharmacopeia Enters Into Licensing Agreement With Bristol-Myers Squibb
GeneGo Enters Into Agreement With Bristol-Myers
Inhibitex Enters Into Licensing Agreement With The University Of Georgia
DynoChem Enters Into Licensing Agreement With Bristol-Myers Squibb
ZymoGenetics Enters Into Licensing Agreement With Bayer Schering Pharma
Bristol-Myers Squibb Enters Into Agreement With Isis Pharma
Inhibitex Enters Into Licensing Agreement With 3M
Bristol-Myers Squibb Signs A Licensing Agreement With Otsuka Pharma
Kosan Biosciences Enters Into Licensing Agreement With Pfizer
Prosidion Enters Into License Agreement With Bristol-Myers Squibb
Xention Enters Into License Agreement With Bristol-Myers Squibb
Bristol-Myers Squibb Enters Into Licensing Agreement With Medivir
Bristol-Myers Enters Into Licensing Agreement With Dainippon Sumitomo For Irbesartan
Pharmacopeia Enters Into Licensing Agreement With Bristol-Myers
Cadence Pharma Enters Into Licensing Agreement With Bristol-Myers Squibb
Kosan Biosciences And Roche Enter Into Cross License Agreement With Bristol-Myers Squibb
Aurobindo Pharma Enters Into A Licensing Agreement With Bristol-Myers Squibb
Aspen Pharmacare Enters Into An Agreement With Bristol-Myers Squibb
Athersys Extends Its Agreement With Bristol-Myers Squibb
Endocyte Enters Into Licensing Agreement With Bristol-Myers Squibb
Inhibitex Files Registration Statement For Public Offering Of Securities For $130 Million
Inhibitex Completes An Underwritten Public Offering For $54.1 Million
ZymoGenetics Completes Public Offering Of Common Stock For $97 Million
Inhibitex Completes Private Placement Of $23 Million
Kosan Biosciences Completes Registered Direct Offering Of $45.5 Million
Kosan Biosciences Completes Private Placement Of $3 Milion
Kosan Biosciences Completes Public Offering Of $25.5 Million
Bristol-Myers Squibb Completes Public Offering Of Senior Unsecured Notes Due 2017 For $750 Million
Bristol-Myers Squibb Completes Public Offering Of 2% Senior Unsecured Notes Due 2022 For $750 Million
Bristol-Myers Squibb Completes Public Offering Of 3.25% Senior Unsecured Notes Due 2042 For $500 Million
Bristol-Myers Completes Public Offering Of 5.45% Senior Notes For $600 Million
Bristol-Myers Completes Public Offering Of 6.125% Senior Notes For $1,000 Million
Bristol-Myers Completes Public Offering Of 5.875% Notes Due 2036 For $1,250 Million
Inhibitex Completes Private Placement Of $0.075 Million
Synergy Pharma Acquires FV-100 From Bristol-Myers Squibb
Paladin Labs Completes Acquisition Of Tempra From Bristol-Myers Squibb
Saba Ilac Acquires Serozil From Bristol-Myers Squibb
Deva Holding Acquires Pharma Products From Bristol-Myers Squibb
Biotica Acquires Polyketide Engineering IP From Bristol-Myers Squibb
Aton Pharma Acquires Marketing Rights For LODOSYN From Bristol-Myers
Taisho Pharma Acquires OTC Drug Trademarks From Bristol-Myers Squibb
Sigma Pharma Acquires Drug Portfolio & Related Assets From Bristol-Myers Squibb
GlaxoSmithKline Acquires Generic Business From Bristol-Myers Squibb
Uman Pharma Acquires Candiac Facility From Bristol Myers-Squibb
GlaxoSmithKline Acquires Eqyptian Business Of Bristol Myers Squibb
Vivolution Acquires Extensive Patent Portfolio From Bristol-Myers Squibb
Lion Corporation Purchases Sales Right For Bufferin And Excedrin From Bristol-Myers
Ranbaxy Labs Acquires US Rights Of Dermatology Products From Bristol-Myers Squibb
Bristol-Myers Squibb Completes Acquisition Of Amylin Pharma For $5.3 Billion
Bristol-Myers Squibb Completes Acquisition Of Inhibitex, Hepatitis C Drug Developer, For $2.5 Billion
Bristol-Myers Squibb Acquires Amira Pharma For $475 Million
Bristol-Myers Squibb Acquires ZymoGenetics
Savient Pharma Announces The Sale Of The Company
Taisho Pharma Acquires PT Bristol-Myers Squibb Indonesia From Bristol-Myers Squibb
Bristol-Myers Squibb Acquires Medarex
GlaxoSmithKline Acquires BMS Pakistan From Bristol-Myers Squibb
Eli Lilly Acquires ImClone Systems
Bristol-Myers Squibb Acquires Kosan Biosciences
Bristol-Myers Squibb Acquires Adnexus Therapeutics
Inhibitex Acquires Fermavir Pharma
List of Figures
Bristol-Myers Squibb Company – Pipeline by Indication, 2012
Bristol-Myers Squibb Company – Pipeline by Stage of Development, 2012
Bristol-Myers Squibb Company – Monotherapy Products in Pipeline, 2012
Bristol-Myers Squibb Company – Combination Treatment Modalities in Pipeline, 2012
Bristol-Myers Squibb Company – Pipeline By Therapeutic Class, 2012
Bristol-Myers Squibb Company – Pipeline By Route of Administration, 2012
Bristol-Myers Squibb Company - Pipeline Products By Mechanism of Action, 2012 261
